Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2021
Price :
$35
*
At a glance
- Drugs Namodenoson (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Can-Fite BioPharma
- 24 Nov 2021 According to a Can-Fite Biopharma media release, Dr. Fishman will deliver a presentation about the study at the 5th Annual NASH Summit 2021 to be held virtually.
- 21 Oct 2021 According to a Can-Fite Biopharma media release, data from this study were published in the Alimentary Pharmacology & Therapeutics, a peer reviewed scientific journal focused on gastroenterology and hepatology.
- 20 Oct 2021 Results published in the Alimentary Pharmacology and Therapeutics